Stock Analysis on Net
Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Common-Size Income Statement 

Cytokinetics Inc., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Research and development revenues 6.96 15.01 29.60 100.00 83.71
License revenues 0.00 77.89 65.38 0.00 16.29
Milestone revenues 1.06 7.10 5.02 0.00 0.00
Realization of revenue participation right purchase agreement 91.98 0.00 0.00 0.00 0.00
Revenues 100.00% 100.00% 100.00% 100.00% 100.00%
Research and development -254.59 -227.09 -173.66 -320.55 -282.96
General and administrative -188.16 -137.45 -94.61 -147.42 -99.30
Operating expenses -442.75% -364.54% -268.27% -467.97% -382.26%
Operating loss -342.75% -264.54% -168.27% -367.97% -282.26%
Interest expense -20.52 -23.34 -28.59 -24.65 -12.05
Loss on settlement of debt -26.37 0.00 0.00 0.00 0.00
Non-cash interest expense on liabilities related to revenue participation right purchase agreements -33.56 -18.31 -40.68 -77.18 -56.40
Interest and other income, net 11.99 0.47 9.55 16.88 13.30
Loss, before income tax provision -411.21% -305.72% -228.00% -452.93% -337.41%
Income tax provision 0.00 0.00 0.00 0.00 0.00
Net loss -411.21% -305.72% -228.00% -452.93% -337.41%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Income statement item Description The company
Operating loss The net result for the period of deducting operating expenses from operating revenues. Cytokinetics Inc. operating loss as a percentage of revenues decreased from 2020 to 2021 and from 2021 to 2022.
Loss, before income tax provision Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Cytokinetics Inc. loss, before income tax provision as a percentage of revenues decreased from 2020 to 2021 and from 2021 to 2022.
Net loss The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Cytokinetics Inc. net loss as a percentage of revenues decreased from 2020 to 2021 and from 2021 to 2022.